Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company. He also informs Roivant’s view of its existing biopharmaceutical subsidiary comp...
Jan 05, 2024•51 min
Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners , providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einstein College of Medicine. Ignacio embraces the Hopkins Biotech Podcast's mission of the pursuit of alternative careers for PhD holders. In this episod...
Dec 18, 2023•44 min
Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting , a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collaboratory Slack Community to work directly with Carina and her team. In this episode, we discuss the state of the biotech job market and offer advice to ...
Nov 01, 2023•57 min
About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology , a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions fo...
Oct 09, 2023•29 min
Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital . In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading and executing full-cycle recruiting across all newcos and portfolio companies. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generat...
Aug 14, 2023•29 min
Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics . Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines targeting biomolecular condensates. Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical School...
Jul 17, 2023•38 min
Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs . BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more than 1 billion dollars in private financing. With a growing number of sites across the globe, Biolabs is enabling company formation and promoting the b...
Apr 17, 2023•36 min
In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology . Surface Oncology’s mission is to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Before becoming CEO, Ro...
Mar 20, 2023•59 min
Brian Culley is the CEO of Lineage Cell Therapeutics , a clinical-stage biotech company whose mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage currently has several programs undergoing clinical and preclinical investigation for indications in ophthalmology, neurology, and oncology. Prior to joining Lineage in 2018, Brian held a number of senior leadership and executive roles at various biotech companies...
Feb 27, 2023•29 min
In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals , a clinical-stage company developing drugs for rare mitochondrial disorders. Their lead clinical candidate REN-001 is currently being investigated in the treatment of p...
Feb 15, 2023•47 min
Adrian is an advisor for several biotech companies in Argentina. Before joining CITES , a venture builder from Argentina, he worked as an advisor for RedCrow VC in San Francisco, and has more than 10 years working in the pharmaceutical industry in companies like Novartis and Merck KGaA. In this episode, we discuss his path from academia to big pharma companies and how he made it to the world of Venture Capital and Venture Building. He also shared his thoughts about the role of big pharma in ecos...
Jan 17, 2023•54 min
Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial. Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions ...
Jan 09, 2023•39 min
Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at industrial scales and the research and development of melanin-based technologies for a variety of commercial applications like shielding and harvesting ra...
Dec 05, 2022•47 min
Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of improved therapeutic agents and transforming oncology treatment paradigms. Dr. Jack Hoppin is the co-founder, Chairman, and Chief Executive Officer of...
Nov 21, 2022•43 min
Dr. Anupam Chakravarty is a researcher whose research interests have straddled the disciplines of biochemistry and genomics with a keen focus on the biology of cancer. Currently, he is a senior scientist developing liquid biopsy assays and products in the precision oncology space at Guardant Health . Prior to joining Guardant Health, he ran his own lab as an Assistant Professor at the University of Michigan Ann Arbor. He obtained his Ph.D. from Memorial Sloan Kettering in New York City and was a...
Nov 14, 2022•40 min
Dr. Tony Russo Ph.D. is the Chairman, CEO, and founder of Russo Partners , a leading public and investor relations firm. He has been a member of the healthcare and technology PR and IR community for more than three decades. As a founder of Noonan/Russo in 1988, he and his colleagues have helped build signature healthcare brands worldwide. A frequent speaker at industry conferences, Tony has published articles and chapters in numerous scientific magazines, medical journals and books. He holds an ...
Oct 31, 2022•55 min
Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences , a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led an...
Oct 03, 2022•46 min
Dr. Shelley Ackerman is an Associate Director & Program Team Lead at Bolt Biotherapeutics . Bolt is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Biotherapeutics’ proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by the immune system. BDC-1001 is a HER2-targeting B...
Sep 05, 2022•32 min
Dr. James Coates is currently the Principal for Health & Human Performance at Decisive Point , an East coast venture capital firm that invests in and supports startups with deep tech and government use cases. James holds a Ph.D. in Cancer Drug Discovery and MSc in Radiation Biology and Oncology, both from the University of Oxford, and he conducted technical diligence for Bain Capital Life Sciences prior to joining Decisive Point. In this episode, we discuss his career path and transition fro...
Aug 22, 2022•24 min
Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics , a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine. Prior to founding the company, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan ...
Aug 08, 2022•38 min
Dr. Steve Doberstein has had a long career leading Research groups at a number of biotech companies, like “XOMA”- a monoclonal antibody discovery and development company, “Five Prime Therapeutics”- a protein and antibody discovery and development company, “Xencor”- a leader in protein engineering and “Exelixis”-a genomics-based drug discovery company. Today is the founder and CEO of Kahiliholo Consulting (based in San Francisco), that supports biotech enterprises and early-stage founders. Prior ...
Jul 25, 2022•58 min
Dr. Daniel Elgort currently serves as the Chief Data and Analytics Officer for M2GEN , a bioinformatics company focused on the acceleration of oncology research discoveries through superior data and analytics services. The company was formed as a spin-off of the Moffitt Cancer Center in Tampa, Florida, serving as the technological hub for an alliance of 18 NCI-designated cancer centers across the country called the ORIEN network. Prior to M2GEN, Dan was Chief Scientific Officer at Covera Health,...
Jul 11, 2022•48 min
Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals , a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies- to improve the quality of life and outcomes for patients fighting cancer. Prior to founding OnQuality, she worked as a Physician-Scientist in numerous medical affairs and leadership roles at the NIH, Bristol-Myers Squibb, Astellas Pharma, Dendreon, and J...
Jun 30, 2022•26 min
Laura Jacoby is currently an Application Specialist at Apprentice.io, an innovative tech company that offers cloud-based solutions that impact pharmaceutical production at every stage of development. Their goal is to introduce digitization of records in an industry that until recently has operated mainly in a paper and pen world. Laura has a career trajectory deeply rooted in pharmaceutical process development and manufacturing sciences working both at the bench and in her capacity as an account...
Jun 21, 2022•32 min
Alex Harding is a Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics , a Boston-based biotech company developing small molecules that alter RNA processing prior to protein translation. Their REMaste r platform “enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon skipping or rescue genetic lesions.” Their technology “can address undrugged disease drivers across therapeutic areas to rapidly bring new medicine...
May 16, 2022•42 min
The crab season is here! If you are a Baltimore resident, you might have enjoyed dozens of our famous blue crabs, perhaps dozens of dozens every year. If you are new to Baltimore, you must have been encouraged to try them. Blue crabs are indeed tasty, but other than their nice savor, what do we know about them? This week on Sci'more podcast, crab biologist Shaun Miller from the Maryland Department of Natural Resources (Twitter: @MarylandDNR) and Maryland fishery scientist Dr. Allison Colden from...
Apr 25, 2022•26 min
Our episode features two leaders at the global specialty pharmaceutical company Kyowa Kirin. Kyowa Kirin has a particular focus on the discovery and development of novel, first-in-class medicines that have a profound impact on patients in multiple therapeutic areas. Rachel Soloff is an executive director of research with expertise in immunology and the discovery of novel monoclonal antibodies and small molecule therapeutic compounds for autoimmune and inflammatory diseases. She oversees the KK U...
Apr 11, 2022•46 min
McKane is a 5th year PhD student in the Department of Population, Family and Reproductive Health at Johns Hopkins Bloomberg School of Public Health She is conducting her PhD project under supervision of Dr. Terri Powell ( https://www.researchbypowell.com/ ) trying to identify how multiple levels of support interact to influence positive sexual health among U.S. adolescents by analyzing nationally representative surveys. McKane is also a mother of two young children, both born during her PhD and ...
Mar 07, 2022•25 min
Dr. Michael Nedelcovych is a Vice President of Equity Research at Cowen Inc. , a diversified financial services firm that operates as a broker dealer and investment manager. Mike works on the large cap pharma equity research team – covering large, multinational pharmaceutical organizations – evaluating the performance of those companies in order to make investment decisions. Prior to his role at Cowen, Mike was a Scientist in the Johns Hopkins Drug Discovery Program, working in the lab of Dr. Ba...
Feb 21, 2022•41 min
Eric Vivier is an SVP, CSO, and co-founder of Innate Pharma , a company developing innovative immunotherapy approaches with the goal of eradicating solid and metastatic tumors in the body. Eric is a Doctor of Veterinary Medicine (DVM) from the Ecole Nationale Vétérinaire de Maisons-Alfort and holds a Ph.D. in Immunology from the Paris University (Paris XI). After completing his post-doctoral fellowship at Harvard Medical School (Dana Farber Cancer Institute), Pr. Vivier joined the Center of Immu...
Feb 07, 2022•47 min
